Pharmaceuticals Australia

Australia Neuropathic Pain Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Australia Neuropathic Pain Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $123.0 Mn Placeholder estimate
Estimate 2025 $131.5 Mn 1.4% of the global market
Projected 2034 $239.8 Mn 82.3% Adds $108.3 Mn over 9 forecast years
CAGR 2025–2034 6.9% Faster than 19% of 183 Pharmaceuticals markets here
Key players 5
  • Australia is 1.4% of the global market.
  • In APAC, the largest is China at $858.3 Mn.
  • Fastest growing: India at 8.2% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$108.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Neuropathic Pain Treatment Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $123.0 Mn — —
2025 (base) $131.5 Mn +$8.5 Mn —
2026 (forecast) $140.6 Mn +$9.1 Mn +6.9%
2027 (forecast) $150.3 Mn +$9.7 Mn +14.3%
2028 (forecast) $160.7 Mn +$10.4 Mn +22.2%
2029 (forecast) $171.8 Mn +$11.1 Mn +30.6%
2030 (forecast) $183.6 Mn +$11.9 Mn +39.6%
2031 (forecast) $196.3 Mn +$12.7 Mn +49.2%
2032 (forecast) $209.8 Mn +$13.5 Mn +59.5%
2033 (forecast) $224.3 Mn +$14.5 Mn +70.5%
2034 (forecast) $239.8 Mn +$15.5 Mn +82.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Neuropathic Pain Treatment Market Analysis at a glance
Market size, 2025$131.5 Mn placeholder estimate
Forecast, 2034$239.8 Mn placeholder estimate
Growth (CAGR), 2025–20346.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, indication and end user (see all)
Key playersPfizer Inc., Eli Lilly and Company, Vertex Pharmaceuticals, Grunenthal, Daiichi Sankyo Company (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials5 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Neuropathic Pain Treatment Market Analysis Executive Summary

Neuropathic pain treatments ease pain from damaged nerves, such as in diabetes, shingles and spinal injury.

Key segments of the neuropathic Pain Treatment market include drug class (Anticonvulsants, Antidepressants and Topical Agents) and indication (Diabetic Neuropathy, Postherpetic Neuralgia and Spinal Cord Injury).

Bar chart: Australia Neuropathic Pain Treatment market size, 2024–2034, placeholder estimates. $123.0 Mn in 2024, $131.5 Mn in 2025 and $239.8 Mn in 2034, 6.9% CAGR.
Australia Neuropathic Pain Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Neuropathic Pain Treatment Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the neuropathic Pain Treatment market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the neuropathic Pain Treatment market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the neuropathic Pain Treatment market.

Competitive Landscape for Neuropathic Pain Treatment Market in Australia

The neuropathic Pain Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Neuropathic Pain Treatment Market in Australia

Neuropathic Pain Treatment in Australia: rules, payment and research

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 5 studies on Neuropathic Pain Treatment that are recruiting, active or about to start in Australia.⁠[3]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for neuropathic Pain Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Neuropathic Pain Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Neuropathic Pain Treatment in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 4th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Neuropathic Pain Treatment market in Australia?
Placeholder estimate: about $131.5 Mn in 2025, rising to about $239.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neuropathic Pain Treatment market in Australia growing?
Placeholder estimate: about 6.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neuropathic Pain Treatment market report cover?
The report splits the market by drug class (Anticonvulsants, Antidepressants, Topical Agents, Opioids and more), indication (Diabetic Neuropathy, Postherpetic Neuralgia, Spinal Cord Injury) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Neuropathic Pain Treatment market?
Key players include Pfizer Inc., Eli Lilly and Company, Vertex Pharmaceuticals, Grunenthal and Daiichi Sankyo Company.
What is driving the Neuropathic Pain Treatment market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the neuropathic Pain Treatment market.
Who regulates Neuropathic Pain Treatment in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Neuropathic Pain Treatment are running in Australia?
5 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on Neuropathic Pain Treatment?
PubMed lists 110 papers on Neuropathic Pain Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Australia

See all

Related on brain and nerves and pain

See the topic